#USA #Stamford #KNB Communications #Gentherm #ThermAffyx

Gentherm Collaborates with KNB Communications

Gentherm, a leader in thermal management and comfort technologies, has joined forces with KNB Communications to enhance the launch of its innovative ThermAffyx™ Patient Safety System. This partnership marks a significant step in addressing patient safety during surgical procedures, integrating warming and securement features into a singular device.

A New Era in Patient Safety

The new device, designed to tackle the common concerns of maintaining patient warmth and securement, emerges from Gentherm's commitment to improving clinical outcomes. Steve Fletcher, Gentherm's SVP and General Manager of Medical, emphasized how the product stemmed from direct surgeon feedback, highlighting a gap in current medical device offerings. He stated, "ThermAffyx is a solution born of clinical need," demonstrating Gentherm's focus on practical, impactful innovations in healthcare.

With KNB Communications as the agency of record, the initiative aims to not only launch ThermAffyx™ but also ensure that the narrative surrounding its development and benefits reaches the right audiences. KNB brings a wealth of experience in healthcare communications, particularly in the medical device space, and is dedicated to crafting compelling stories that resonate with clinicians, investors, and patients alike.

Expertise Meets Innovation

Chintan Shah, President of KNB Communications, expressed enthusiasm about the collaboration, noting the agency's mission aligns with Gentherm's pioneering efforts in healthcare advancements. KNB's role will include developing strategic communication plans and media relations efforts to effectively present the benefits of ThermAffyx™ to the marketplace. Shah remarked, "At KNB Communications, we aim to partner with industry leaders announcing medical breakthroughs," emphasizing their commitment to impactful storytelling in healthcare.

As ThermAffyx gears up for its market introduction, it stands to provide significant advantages in surgical settings, streamlining processes and enhancing patient comfort. The device's development has been characterized by a responsive design approach, focusing on clinician needs and patient safety.

Regulatory Steps and Future Prospects

Earlier this year, Gentherm submitted a 510(k) Class II premarket notification to the FDA for ThermAffyx™, anticipating clearance in May 2026. Gaining FDA approval would solidify its entry into the market as a novel solution for hospitals and surgical centers, a sector increasingly prioritizing patient-centered care.

Looking toward the future, Gentherm is actively advancing its portfolio, which includes a vast range of thermal management solutions in automotive and medical fields. With over 14,000 employees and facilities spread over 13 countries, the company's outreach and impact are extensive. In the previous year, Gentherm recorded significant sales revenue of approximately $1.5 billion, underscoring its market influence and commitment to innovation.

A Bright Future for Patient Care

This partnership not only indicates Gentherm's proactive approach to product innovation but also highlights the importance of effective communication in the healthcare sector. As technologies evolve, the need for clear, credible narratives becomes ever more critical to ensure that innovations effectively reach those who will benefit from them—the patients.

With ThermAffyx™, Gentherm, alongside KNB Communications, is poised to make a substantial impact on surgical practices, demonstrating how strategic partnerships can lead to groundbreaking advancements in patient care. As the launch date approaches, the healthcare community is eager to see how this innovative device will transform surgical environments and enhance patient safety protocols.